The BioMed X Institute | WebDisclosure

Switch to English

8296	Sociétés
114902	Mots-clés
55332	Articles
62460	Communiqués

Accueil
Sociétés
The BioMed X Institute

BRÈVE

publiée le 30/04/2024 à 11:05, il y a 6 mois 21 jours

New Partnership Between BioMed X Institute and Merck Focuses on Immuno-Oncology

Cancer Research BioMed X Institute Immunotherapy Merck Tumor Immunogenicity
COMMUNIQUÉ DE PRESSE

publié le 30/04/2024 à 11:00, il y a 6 mois 21 jours

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Biomedical research institute, BioMed X, partners with Merck to develop novel immunotherapeutic strategies to enhance tumor immunogenicity for cancer patients

Cancer Research Immunotherapy Merck Tumor Immunogenicity BioMed X
COMMUNIQUÉ DE PRESSE

publié le 06/02/2024 à 16:00, il y a 9 mois 14 jours

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
BioMed X Institute and Universitatsmedizin Mannheim researchers publish results of collaboration on new neoepitope vaccine in diffuse midline glioma in Science Advances

BioMed X Institute Universitatsmedizin Mannheim Neoepitope Vaccine Diffuse Midline Glioma Science Advances
COMMUNIQUÉ DE PRESSE

publié le 07/11/2023 à 12:00, il y a 1 année

BioMed X Launches a New Call for Application in Autoimmune Disease Research
COMMUNIQUÉ DE PRESSE

publié le 31/10/2023 à 17:00, il y a 1 année

BioMed X and AbbVie Start New Research Project in the USA
COMMUNIQUÉ DE PRESSE

publié le 29/06/2023 à 11:00, il y a 1 année 4 mois

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
COMMUNIQUÉ DE PRESSE

publié le 27/04/2023 à 14:00, il y a 1 année 6 mois

BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus
COMMUNIQUÉ DE PRESSE

publié le 04/04/2023 à 11:00, il y a 1 année 7 mois

BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies

Les Echos

Publié le 21/11/2024 à 06:58, il y a 6 heures 52 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 52 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 52 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 42 minutes

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 30 minutes

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 21/11/2024 à 13:30, il y a 20 minutes

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 20 minutes

Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 50 minutes

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 50 minutes

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 50 minutes

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 13:41, il y a 9 minutes

Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 13:15, il y a 35 minutes

NOTICE OF ANNUAL GENERAL MEETING
Publié le 21/11/2024 à 12:35, il y a 1 heure 15 minutes

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 35 minutes

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Publié le 21/11/2024 à 12:06, il y a 1 heure 43 minutes

IVU AG publishes Quarterly Report Q3-2024